Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Trial Could Help Pick Best Covid Vaccine Boosters

Initial Results Due In September

Executive Summary

Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.

You may also be interested in...



Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result

Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.

Six Questions For GSK Ahead Of Crucial Investor Day

Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.

US Backs Oral COVID-19 Therapies And ‘Next Pandemic’ Drug Discovery With $3.2bn

Aiming to mimic public-private COVID-19 vaccine success, the US NIH will fund pandemic drug research, including taking candidates up to Phase II.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel